Send a Tweet
Most Popular Choices
Share on Facebook 19 Share on Twitter Printer Friendly Page More Sharing
Best Web OpEds    H3'ed 5/22/19

Ocasio-Cortez confronts Gilead CEO for nearly $2K price tag on HIV drug that costs $8 in Australia

Quicklink Submitted By   No comments
Message Stephen Fox
Become a Fan
  (31 fans)

Rep. Ocasio-Cortez examine the Gilead's pricing for an HIV prevention drug known as Truvada for PrEP
(Image by YouTube, Channel: Oversight Committee)
  Details   DMCA

Ocasio-Cortez: "Gilead made $3 billion in profits from Truvada in 2018? CEO O'Day:"$3 billion in revenue." "The current list price is $2,000 a month in the United States, correct?" O'Day: "It's $1,780 in the United States." Ocasio-Cortez: "Why is it $8 in Australia?" O'Day: "Truvada has patent protection in US; in the rest of the world it is generic. It will be generically available in US as of September 2020."

Ocasio-Cortez: "We the public, we the people, developed this drug. We paid for this drug, we lead and developed all the patents to create prep and then that patent has been privatized despite the fact that the patent is owned by the public. There's no reason this should be $2,000 a month, people are dying because of it and there's no enforceable reason for it."

Donald Rumsfeld was Chairman at Gilead until named to Bush's cabinet. Gilead patented the deadly Tamiflu.

Read the rest of the story HERE:

Rate It | View Ratings

Stephen Fox Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Early in the 2016 Primary campaign, I started a Facebook group: Bernie Sanders: Advice and Strategies to Help Him Win! As the primary season advanced, we shifted the focus to advancing Bernie's legislation in the Senate, particularly the (more...)

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
   (Opens new browser window)

To View Comments or Join the Conversation:

Tell A Friend